Cargando…

Investigator led trials: challenges and opportunities

Detalles Bibliográficos
Autor principal:	Sandercock, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287815/ http://dx.doi.org/10.1186/1745-6215-12-S1-A94

Ejemplares similares

ART for prevention: opportunities, challenges and predictions
por: Cohen, Myron S
Publicado: (2014)

Implementation of TasP: challenges and opportunities
por: Lange, Joep
Publicado: (2014)

The influenza challenge
por: Nguyen, Tim, et al.
Publicado: (2010)

I-9 Opportunities and challenges of pharmaceutical research and development today
por: Middleton, L.
Publicado: (2011)

The challenges of contemporary wound care
por: McGuiness, Bill
Publicado: (2011)

Ageing with HIV: next challenges
por: Fisher, Martin
Publicado: (2010)

Lessons and challenges from RA
por: Conaghan, Philip
Publicado: (2014)

Oral food challenges: practical aspects
por: Rudzeviciene, Odilija
Publicado: (2011)

Development of ICD 11: changes and challenges
por: Zafar, A, et al.
Publicado: (2012)

Challenges in assessing the potential allergenicity of biotechnology products
por: Goodman, Richard
Publicado: (2011)

Immunotherapy in HIV infection; current and future challenges
por: Lévy, Yves
Publicado: (2010)

Introductory lecture: Diagnosis of food allergy: when is an oral challenge positive
por: Niggemann, Bodo
Publicado: (2011)

PReS13-SPK-1253: Challenges in nursing care with the new biologics for JIA
por: Livermore, P
Publicado: (2013)

What does it take to be healthy? Investigating immune-deficiency in non-immunodeficient scenarios
por: Binda, Elisa, et al.
Publicado: (2012)

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4
por: Sharma, P
Publicado: (2014)

Equivalence and non inferiority trials
por: D’Agostino, Ralph B
Publicado: (2011)

EDI200 therapeutic trial
por: Huttner, Kenneth
Publicado: (2012)

The madness of HIV prevention trials
por: McCormack, S
Publicado: (2015)

Discussion session: biomarker trials
Publicado: (2015)

Seven myths of randomisation in clinical trials
por: Senn, Stephen
Publicado: (2011)

Randomised controlled trials of complex interventions
por: Norrie, John
Publicado: (2011)

Removing unnecessary obstacles to randomised trials
por: Collins, Rory
Publicado: (2013)

Strategies for handling missing data in randomised trials
por: White, Ian R
Publicado: (2011)

Identifying appropriate phase II trial designs
por: Brown, Sarah R
Publicado: (2011)

Trials in rare diseases: the need to think differently
por: Billingham, Lucinda, et al.
Publicado: (2011)

Using biomarkers prospectively in adaptive clinical trials
por: Berry, Donald A
Publicado: (2011)

Science in a crisis: conducting clinical trials in an emergency
por: Horby, P
Publicado: (2015)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

The UK Medical Research Council and clinical trials, 1934-1960
por: Chalmers, Iain
Publicado: (2013)

Science, society and biosafety of a field trial with transgenic biofuel poplars
por: Van Acker, Rebecca, et al.
Publicado: (2011)

Recruitment to trials - why is it hard and how might we make it less so?
por: Treweek, Shaun
Publicado: (2011)

When to decide to enroll a TTR-FAP patient in a Clinical Trial?
por: Buades, Juan
Publicado: (2015)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

Streamlining regulation of clinical trials – update on the Academy of Medical Sciences review and government’s response
por: Ford, Gary A
Publicado: (2011)

Using economic modelling to contribute to the prioritisation and design and clinical trials: ready for prime time
por: Sculpher, Mark
Publicado: (2011)

Statistical issues in the analysis of non-pharmacological therapy trials with clustering by care-provider or therapy group
por: Roberts, Chris
Publicado: (2011)

S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial
por: Schmoll, H, et al.
Publicado: (2014)

Interrogating the architecture of cancer genomes
por: Campbell, Peter
Publicado: (2011)

Health workforce issues for podiatry
por: Brooks, Peter M
Publicado: (2011)

Dermatologic aspects of ectodermal dysplasias
por: Itin, Peter H
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bppfulb5b6ksl19h98uablj9b3